报价延迟最少15分钟:2025/09/06 07:08 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
341.8 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.69/7.13
|
|
企业价值
35.28B
|
| 资产负债 |
|
每股账面净值
34.27
|
| 现金流量 |
|
现金流量率
0.02
|
| 损益表 |
|
收益
238.39M
|
|
每股收益
17.01
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/09/06 07:08 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue. |
